Would you like to receive important updates about Regeneron Pharmaceuticals Inc like earnings dates and more?
The Year To Date (YTD) return is -13.19%.
The 52 Week Low stock price is 313.53 set on Wed, Feb 14, 2018 which is 6 days ago.
The current price per share is 5.94% above the 52 week low.
The 52 Week High stock price is $543.55 set on Thu, Jun 22, 2017 which is 243 days ago.
The current price per share is -38.89% below the 52 week high.
The All Time High stock price is $605.93 set on Tue, Aug 4, 2015 which is 931 days ago.
The current price per share is -45.18% below the all time high.
The Regeneron 5 year stock chart shows the historical prices over the previous 60 months.
The Regeneron 1 year stock chart shows the historical prices over the previous 12 months.
The 50 Day Moving Average is at $491.05 which is 32.36% above the stock price of $332.15.
The 200 Day Moving Average is at 419.03 which is 20.73% above the stock price of $332.15.
Because both the 50 DMA and 200 DMA are above the current stock price, this can be considered a bearish technical indicator.
Since the stock price is very far from both moving averages, a price retracement towards the moving averages should not be unexpected.
Regeneron Pharmaceuticals Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $35.69 Billion.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
For more information and analysis about Regeneron Pharmaceuticals Inc, visit their web site at http://www.regeneron.com. For a real time price lookup on this ticker, REGN, visit Google Finance and Bloomberg.
Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .
The EPS is $10.32.
The P/E Ratio is 32.18%.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Regeneron Pharmaceuticals Inc was Wed, Nov 8, 2017.
Since this earnings release 104 days ago, the stock price is down by -17.86%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The most recent Earnings Release Date was on Thu, Feb 8, 2018, which was 12 days ago.
Since this earnings date, the stock price is down by -0.74%.
REGN currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.